

Global Epigenetics Drugs & Diagnostic Technologies Market Size study, by Drug Type (DNA Methyltransferases (DNMTs) Inhibitors [Azacitidine, Decitabine, and Others], Histone Deacetylases (HDACs) Inhibitors [Vorinostat, Romidepsin, and Others], Histone Methyltransferase (HMT) Inhibitors, and Others), Diagnostic Technologies (DNA Methylation, Histone Modification Analysis, and Others), Application (Oncology, Neurology, Autoimmune Diseases, and Others), End User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G328A1178437EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G328A1178437EN

Abstracts

Global Epigenetics Drugs & Diagnostic Technologies Market is valued at approximately USD 8.23 billion in 2023 and is anticipated to grow with a remarkable CAGR of more than 21.90% over the forecast period 2024-2032. Epigenetic mechanisms have fundamentally revolutionized our understanding of gene expression regulation, making epigenetics-targeted drugs and diagnostic technologies central to the next generation of personalized medicine. These approaches, targeting reversible modifications such as DNA methylation and histone acetylation, are opening promising therapeutic pathways for previously intractable conditions, particularly in oncology. As pharmaceutical pipelines increasingly incorporate epigenetic targets, there is a dynamic shift from symptom-based interventions to mechanistically-driven therapies with molecular precision.

Accelerating investments in biomarker-driven research and next-gen sequencing have vastly enhanced the ability to stratify patients and design precision-based treatment regimens. This advancement is paralleled by the emergence of epigenetic diagnostic platforms that allow for early detection, disease staging, and treatment monitoring, especially in cancers with poor prognoses. The introduction of approved epigenetic drugs, including DNMT and HDAC inhibitors, has validated the clinical relevance of this modality. However, pricing complexities, patent expiration risks, and the need for skilled interpretation of epigenomic data continue to pose hurdles. Nonetheless, collaborations between academic centers, pharma giants, and tech companies are working toward closing these translational gaps.

A particularly compelling growth enabler is the convergence of AI-powered analytics with epigenomic databases, which allows predictive modeling of therapeutic response and disease susceptibility. This data-centric approach is fueling the development of novel diagnostic assays and companion diagnostics, aligning drug development with regulatory preferences for personalized care. Furthermore, hospitals and diagnostic labs are increasingly deploying non-invasive liquid biopsies for epigenetic profiling, thus improving patient compliance and accessibility to high-value tests. As the ecosystem evolves, even orphan diseases and neurological conditions are benefiting from epigenetics-guided research, expanding the therapeutic horizon.

The competitive landscape is also undergoing a seismic transformation. Major players are rapidly diversifying their product portfolios through mergers, licensing agreements, and co-development partnerships. Startups are disrupting traditional models with innovative delivery platforms such as nanoparticle-mediated gene silencing and CRISPR-based epigenome editing. Governments and health regulatory bodies are also actively involved, offering incentives for rare disease research and funding public-private consortia. Collectively, these developments are fostering a robust pipeline that spans early discovery to post-market surveillance.

From a geographical standpoint, North America leads the market owing to its early adoption of epigenetics in clinical settings, strong R&D funding, and the presence of regulatory agencies that support rapid drug approvals. Europe is close behind, with nations such as Germany and the UK investing in molecular diagnostics infrastructure. Asia Pacific is projected to exhibit the highest growth rate over the next decade, driven by the expansion of precision medicine programs in China, India, and Japan. Meanwhile, Latin America and the Middle East & Africa are increasingly exploring diagnostic applications through partnerships and pilot studies.

Major market player included in this report are:

Merck & Co., Inc.

Roche Holding AG

Eisai Co., Ltd.

Novartis AG

Celgene Corporation

GlaxoSmithKline plc

AbbVie Inc.

Oryzon Genomics S.A.

Syndax Pharmaceuticals, Inc.

Illumina, Inc.

Agilent Technologies, Inc.

Exact Sciences Corporation

Zymo Research Corporation

PerkinElmer Inc.

Active Motif, Inc.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

DNA Methyltransferases (DNMTs) Inhibitors

o Azacitidine

o Decitabine

o Others

Histone Deacetylases (HDACs) Inhibitors

o Vorinostat

o Romidepsin

o Others

Histone Methyltransferase (HMT) Inhibitors

Others

By Diagnostic Technologies:

DNA Methylation

Histone Modification Analysis

Others

By Application:

Oncology

Neurology

Autoimmune Diseases

Others

By End User:

Hospitals & Clinics

Diagnostic Centers

Others

By Region: North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year: 2022

Base year: 2023

Forecast period: 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032

Annualized revenues and regional level analysis for each market segment

Detailed analysis of geographical landscape with country-level analysis of major regions

Competitive landscape with information on major players in the market

Analysis of key business strategies and recommendations on future market approach

Analysis of competitive structure of the market

Demand side and supply side analysis of the market

Contents

CHAPTER 1. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET EXECUTIVE SUMMARY

- 1.1. Global Epigenetics Drugs & Diagnostic Technologies Market Size & Forecast (2022 – 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Type
 - 1.3.2. By Diagnostic Technologies
 - 1.3.3. By Application
 - 1.3.4. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET DYNAMICS

3.1. Market Drivers

3.1.1. Advancement in Epigenetic Therapeutics Targeting DNA Methylation and Histone Modification

3.1.2. Rising Investment in Biomarker-Driven Research and Next-Gen Sequencing

3.1.3. Integration of AI-Powered Analytics with Epigenomic Data

3.2. Market Challenges

3.2.1. Pricing Complexities and Reimbursement Issues

3.2.2. Patent Expiration Risks and Generic Competition

3.2.3. Requirement for Skilled Interpretation of Epigenomic Data

3.3. Market Opportunities

3.3.1. Development of Non-Invasive Liquid Biopsy-Based Diagnostics

3.3.2. Expansion into Neurological and Orphan Disease Applications

3.3.3. Partnerships and Public-Private Consortia in Emerging Regions

CHAPTER 4. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

4.1.1. Bargaining Power of Suppliers

4.1.2. Bargaining Power of Buyers

4.1.3. Threat of New Entrants

4.1.4. Threat of Substitutes

4.1.5. Competitive Rivalry

4.1.6. Futuristic Approach to Porter's 5 Force Model

4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

4.2.1. Political

4.2.2. Economical

4.2.3. Social

4.2.4. Technological

4.2.5. Environmental

4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET SIZE & FORECASTS BY DRUG TYPE 2022–2032

- 5.1. Segment Dashboard
- 5.2. Global Market: DNA Methyltransferases (DNMTs) Inhibitors Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
 - 5.2.1. Azacitidine
 - 5.2.2. Decitabine
 - 5.2.3. Others
- 5.3. Global Market: Histone Deacetylases (HDACs) Inhibitors Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
 - 5.3.1. Vorinostat
 - 5.3.2. Romidepsin
 - 5.3.3. Others
- 5.4. Global Market: Histone Methyltransferase (HMT) Inhibitors Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.5. Global Market: Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 6. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET SIZE & FORECASTS BY DIAGNOSTIC TECHNOLOGIES 2022–2032

- 6.1. Segment Dashboard
- 6.2. Global Market: DNA Methylation Analysis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.3. Global Market: Histone Modification Analysis Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.4. Global Market: Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 7. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET SIZE & FORECASTS BY APPLICATION 2022–2032

- 7.1. Segment Dashboard
- 7.2. Global Market: Oncology Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.3. Global Market: Neurology Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

7.4. Global Market: Autoimmune Diseases Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

7.5. Global Market: Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 8. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET SIZE & FORECASTS BY END USER 2022–2032

8.1. Segment Dashboard

8.2. Global Market: Hospitals & Clinics Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

8.3. Global Market: Diagnostic Centers Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

8.4. Global Market: Others Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

CHAPTER 9. GLOBAL EPIGENETICS DRUGS & DIAGNOSTIC TECHNOLOGIES MARKET SIZE & FORECASTS BY REGION 2022–2032

9.1. North America Market

9.1.1. U.S. Market

9.1.1.1. Drug Type breakdown size & forecasts, 2022–2032

9.1.1.2. Diagnostic Technologies breakdown size & forecasts, 2022–2032

9.1.1.3. Application breakdown size & forecasts, 2022–2032

9.1.1.4. End User breakdown size & forecasts, 2022–2032

9.1.2. Canada Market

9.2. Europe Market

9.2.1. UK Market

9.2.2. Germany Market

9.2.3. France Market

9.2.4. Spain Market

9.2.5. Italy Market

9.2.6. Rest of Europe Market

9.3. Asia Pacific Market

9.3.1. China Market

9.3.2. India Market

9.3.3. Japan Market

9.3.4. Australia Market

9.3.5. South Korea Market

9.3.6. Rest of Asia Pacific Market

9.4. Latin America Market

- 9.4.1. Brazil Market
- 9.4.2. Mexico Market
- 9.4.3. Rest of Latin America Market
- 9.5. Middle East & Africa Market
 - 9.5.1. Saudi Arabia Market
 - 9.5.2. South Africa Market
 - 9.5.3. Rest of Middle East & Africa Market

CHAPTER 10. COMPETITIVE INTELLIGENCE

- 10.1. Key Company SWOT Analysis
 - 10.1.1. Merck & Co., Inc.
 - 10.1.2. Roche Holding AG
 - 10.1.3. Eisai Co., Ltd.
- 10.2. Top Market Strategies
- 10.3. Company Profiles
 - 10.3.1. Merck & Co., Inc.
 - 10.3.1.1. Key Information
 - 10.3.1.2. Overview
 - 10.3.1.3. Financial (Subject to Data Availability)
 - 10.3.1.4. Product Summary
 - 10.3.1.5. Market Strategies
 - 10.3.2. Novartis AG
 - 10.3.3. Celgene Corporation
 - 10.3.4. GlaxoSmithKline plc
 - 10.3.5. AbbVie Inc.
 - 10.3.6. Oryzon Genomics S.A.
 - 10.3.7. Syndax Pharmaceuticals, Inc.
 - 10.3.8. Illumina, Inc.
 - 10.3.9. Agilent Technologies, Inc.
 - 10.3.10. Exact Sciences Corporation
 - 10.3.11. Zymo Research Corporation
 - 10.3.12. PerkinElmer Inc.
 - 10.3.13. Active Motif, Inc.

CHAPTER 11. RESEARCH PROCESS

- 11.1. Research Process
 - 11.1.1. Data Mining

- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
- 11.2. Research Attributes

I would like to order

Product name: Global Epigenetics Drugs & Diagnostic Technologies Market Size study, by Drug Type (DNA Methyltransferases (DNMTs) Inhibitors [Azacitidine, Decitabine, and Others], Histone Deacetylases (HDACs) Inhibitors [Vorinostat, Romidepsin, and Others], Histone Methyltransferase (HMT) Inhibitors, and Others), Diagnostic Technologies (DNA Methylation, Histone Modification Analysis, and Others), Application (Oncology, Neurology, Autoimmune Diseases, and Others), End User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G328A1178437EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G328A1178437EN.html>